Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Clinical proteomics: Insights from IGF-I

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{a522325c168246ef8ff9f3ea9d008ac2,
title = "Clinical proteomics: Insights from IGF-I",
abstract = "Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.",
keywords = "Journal Article, Review",
author = "Jakob Albrethsen and Hanne Frederiksen and Johannsen, {Trine Holm} and Anna-Maria Andersson and Anders Juul",
note = "Copyright {\textcopyright} 2017 Elsevier B.V. All rights reserved.",
year = "2018",
month = feb,
doi = "10.1016/j.cca.2017.11.034",
language = "English",
volume = "477",
pages = "18--23",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Clinical proteomics

T2 - Insights from IGF-I

AU - Albrethsen, Jakob

AU - Frederiksen, Hanne

AU - Johannsen, Trine Holm

AU - Andersson, Anna-Maria

AU - Juul, Anders

N1 - Copyright © 2017 Elsevier B.V. All rights reserved.

PY - 2018/2

Y1 - 2018/2

N2 - Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.

AB - Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.

KW - Journal Article

KW - Review

U2 - 10.1016/j.cca.2017.11.034

DO - 10.1016/j.cca.2017.11.034

M3 - Review

C2 - 29196187

VL - 477

SP - 18

EP - 23

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -

ID: 52794201